QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wedbush-reiterates-outperform-on-immunome-maintains-33-price-target

Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $33 price target.

 piper-sandler-maintains-overweight-on-immunome-lowers-price-target-to-23

Piper Sandler analyst Biren Amin maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $27 to ...

 immunome-q2-eps-060-misses-039-estimate-sales-236m-miss-255m-estimate

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.39) by...

 nectin-therapeutics-enters-global-exclusive-license-agreement-with-immunome-immunome-receives-exclusive-rights-to-panel-of-antibodies-targeting-an-undisclosed-target

Under the terms of the agreement, Nectin granted Immunome an exclusive, worldwide, all-fields license to monoclonal antibodies ...

 piper-sandler-initiates-coverage-on-immunome-with-overweight-rating-announces-price-target-of-27

Piper Sandler analyst Biren Amin initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rating and announces Price T...

 immunome-form-4-filing-shows-president-and-ceo-clay-b-siegall-bought-100000-shares-of-stock-at-a-price-of-1388share

-  SEC Filing

 immunome-promotes-max-rosett-to-cfo-effective-may-9

Rosett most recently held the role of Executive Vice President, Operations, in addition to serving as Immunome's Interim Ch...

 immunome-q1-eps-251-misses-069-estimate-sales-103m-miss-250m-estimate

Immunome (NASDAQ:IMNM) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $(0.69) by...

 jp-morgan-initiates-coverage-on-immunome-with-overweight-rating-announces-price-target-of-24

JP Morgan analyst Brian Cheng initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rating and announces Price Targ...

 guggenheim-initiates-coverage-on-immunome-with-buy-rating-announces-price-target-of-35

Guggenheim analyst Michael Schmidt initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target...

 immunome-files-for-shelf-of-up-to-22m-shares-of-common-stock-by-selling-stockholder

- SEC Filing

 immunome-inc-filed-prospectus-relates-to-proposed-resale-from-time-to-time-by-selling-stockholder-of-23m-shares-or-shares-of-common-stock

- SEC Filing

 wedbush-maintains-outperform-on-immunome-raises-price-target-to-33

Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $27 t...

 immunome-q4-adj-eps-015-beats-028-estimate-sales-383m-beat-207m-estimate

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.28) by 4...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION